Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.
Breast cancer
HER2/neu receptor
capecitabine
lapatinib
metastasis
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
12
2022
accepted:
03
01
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine. Retrospective data on HER2-positive metastatic breast cancer patients who received lapatinib and capecitabine were analyzed. Survival outcome was obtained with Cox regression analysis and the Kaplan-Meier method. The study included 102 patients. Forty-four (43.1%) patients had These results have demonstrated the effectiveness of lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Furthermore, unfavorable prognostic factors for progression-free survival were shown to be hormone-negative tumor,
Identifiants
pubmed: 37025570
doi: 10.4274/ejbh.galenos.2023.2022-12-4
pii: 59075
pmc: PMC10071882
doi:
Types de publication
Journal Article
Langues
eng
Pagination
128-133Informations de copyright
©Copyright 2023 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Oncol Lett. 2020 Dec;20(6):378
pubmed: 33154776
Future Oncol. 2021 Nov;17(33):4635-4647
pubmed: 34463120
Mol Biol Int. 2014;2014:852748
pubmed: 25276427
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
Clin Cancer Res. 2022 Aug 2;28(15):3329-3341
pubmed: 35727144
Oncologist. 2010;15(9):924-34
pubmed: 20736298
Neuro Oncol. 2015 Feb;17(2):289-95
pubmed: 25015089
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Ann Oncol. 2011 Mar;22(3):625-630
pubmed: 20724575
Cancer Res. 2006 Feb 1;66(3):1630-9
pubmed: 16452222
BMC Cancer. 2012 Jul 28;12:322
pubmed: 22839200
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641
pubmed: 27956436
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Surg Neurol Int. 2019 Jun 28;10:131
pubmed: 31528467
Breast Cancer Res Treat. 2008 Dec;112(3):533-43
pubmed: 18188694
PLoS One. 2012;7(7):e39943
pubmed: 22848366
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Clin Breast Cancer. 2016 Feb;16(1):38-44
pubmed: 26642810
J Cancer. 2020 Mar 5;11(11):3327-3333
pubmed: 32231738
Eur J Cancer. 2017 Oct;84:141-148
pubmed: 28810186